PRELUDE THERAPEUTICS INC Operating Expenses
PRELUDE THERAPEUTICS INC (PRLD) reported Operating Expenses of $21.16 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-11
- PRELUDE THERAPEUTICS INC operating expenses for the quarter ending 2026-06-30 was $21.16M, a 34.28% decline year-over-year.
- PRELUDE THERAPEUTICS INC operating expenses for the quarter ending 2026-03-31 was $18.76M, a 45.80% decline year-over-year.
- PRELUDE THERAPEUTICS INC operating expenses for the quarter ending 2025-12-31 was $22.99M, a 39.24% decline year-over-year.
- PRELUDE THERAPEUTICS INC operating expenses for the quarter ending 2025-09-30 was $26.92M, a 27.98% decline year-over-year.
- PRELUDE THERAPEUTICS INC operating expenses for fiscal 2025 was $116.71M, a 20.45% decline from fiscal 2024.
- PRELUDE THERAPEUTICS INC operating expenses for fiscal 2024 was $146.71M, a 10.91% increase from fiscal 2023.
- PRELUDE THERAPEUTICS INC operating expenses for fiscal 2023 was $132.28M, a 7.07% increase from fiscal 2022.
- PRELUDE THERAPEUTICS INC operating expenses for fiscal 2022 was $123.54M, a 8.62% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $21.16M 10-Q · filed 2026-08-11 | $39.91M 10-Q · filed 2026-08-11 | $62.90M derived: sum of 3 quarters · filed 2026-08-11 | $89.82M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $18.76M 10-Q · filed 2026-05-12 | $41.74M derived: sum of 2 quarters · filed 2026-05-12 | $68.66M derived: sum of 3 quarters · filed 2026-05-12 | $100.86M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $22.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $49.91M derived: sum of 2 quarters · filed 2026-03-10 | $82.10M derived: sum of 3 quarters · filed 2026-08-11 | $116.71M 10-K · filed 2026-03-10 |
| 2025-09-30 | $26.92M 10-Q · filed 2025-11-12 | $59.11M derived: sum of 2 quarters · filed 2026-08-11 | $93.72M 10-Q · filed 2025-11-12 | $131.55M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $32.19M 10-Q · filed 2026-08-11 | $66.80M 10-Q · filed 2026-08-11 | $104.63M derived: sum of 3 quarters · filed 2026-08-11 | $142.01M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $34.61M 10-Q · filed 2026-05-12 | $72.44M derived: sum of 2 quarters · filed 2026-05-12 | $109.81M derived: sum of 3 quarters · filed 2026-05-12 | $146.98M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $37.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $75.21M derived: sum of 2 quarters · filed 2026-03-10 | $112.37M derived: sum of 3 quarters · filed 2026-03-10 | $146.71M 10-K · filed 2026-03-10 |
| 2024-09-30 | $37.38M 10-Q · filed 2025-11-12 | $74.54M derived: sum of 2 quarters · filed 2025-11-12 | $108.88M 10-Q · filed 2025-11-12 | $146.26M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $37.16M 10-Q · filed 2025-08-14 | $71.51M 10-Q · filed 2025-08-14 | $108.89M derived: sum of 3 quarters · filed 2025-08-14 | $142.27M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $34.34M 10-Q · filed 2025-05-06 | $71.72M derived: sum of 2 quarters · filed 2025-05-06 | $105.11M derived: sum of 3 quarters · filed 2025-05-06 | $137.50M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $37.38M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $70.76M derived: sum of 2 quarters · filed 2025-03-10 | $103.16M derived: sum of 3 quarters · filed 2025-03-10 | $132.28M 10-K · filed 2025-03-10 |
| 2023-09-30 | $33.38M 10-Q · filed 2024-11-06 | $65.78M derived: sum of 2 quarters · filed 2024-11-06 | $94.90M 10-Q · filed 2024-11-06 | $128.28M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $32.40M 10-Q · filed 2024-08-12 | $61.51M 10-Q · filed 2024-08-12 | $94.90M derived: sum of 3 quarters · filed 2024-08-12 | $125.30M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $29.11M 10-Q · filed 2024-05-07 | $62.50M derived: sum of 2 quarters · filed 2024-05-07 | $92.91M derived: sum of 3 quarters · filed 2024-05-07 | $122.37M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $33.38M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $63.79M derived: sum of 2 quarters · filed 2024-02-15 | $93.25M derived: sum of 3 quarters · filed 2024-02-15 | $123.54M 10-K · filed 2024-02-15 |
| 2022-09-30 | $30.41M 10-Q · filed 2023-11-01 | $59.87M derived: sum of 2 quarters · filed 2023-11-01 | $90.16M 10-Q · filed 2023-11-01 | $123.17M derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-06-30 | $29.46M 10-Q · filed 2023-08-03 | $59.75M 10-Q · filed 2023-08-03 | $92.76M derived: sum of 3 quarters · filed 2023-08-03 | $123.59M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $30.29M 10-Q · filed 2023-05-08 | $63.30M derived: sum of 2 quarters · filed 2023-05-08 | $94.13M derived: sum of 3 quarters · filed 2023-05-08 | $122.06M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | $33.01M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $63.85M derived: sum of 2 quarters · filed 2023-03-15 | $91.77M derived: sum of 3 quarters · filed 2023-03-15 | $113.73M 10-K · filed 2023-03-15 |
| 2021-09-30 | $30.84M 10-Q · filed 2022-11-14 | $58.76M derived: sum of 2 quarters · filed 2022-11-14 | $80.72M 10-Q · filed 2022-11-14 | $100.17M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $27.92M 10-Q · filed 2022-08-09 | $49.89M 10-Q · filed 2022-08-09 | $69.33M derived: sum of 3 quarters · filed 2022-08-09 | $87.48M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $21.97M 10-Q · filed 2022-05-10 | $41.41M derived: sum of 2 quarters · filed 2022-05-10 | $59.56M derived: sum of 3 quarters · filed 2022-05-10 | $70.99M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $19.45M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $37.59M derived: sum of 2 quarters · filed 2022-03-17 | $49.03M derived: sum of 3 quarters · filed 2022-03-17 | $58.76M 10-K · filed 2022-03-17 |
| 2020-09-30 | $18.14M 10-Q · filed 2021-11-12 | $29.58M derived: sum of 2 quarters · filed 2021-11-12 | $39.32M 10-Q · filed 2021-11-12 | $49.41M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | $11.44M 10-Q · filed 2021-08-12 | $21.17M 10-Q · filed 2021-08-12 | $31.27M derived: sum of 3 quarters · filed 2021-08-12 | $38.15M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $9.74M 10-Q · filed 2021-05-11 | $19.83M derived: sum of 2 quarters · filed 2021-05-11 | $26.72M derived: sum of 3 quarters · filed 2021-05-11 | |
| 2019-12-31 | $10.10M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $16.98M derived: sum of 2 quarters · filed 2021-03-16 | $28.11M 10-K · filed 2021-03-16 | |
| 2019-09-30 | $6.88M 10-Q · filed 2020-11-10 | $18.01M 10-Q · filed 2020-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |